Boston Scientific (BSX)
(Real Time Quote from BATS)
$76.48 USD
+0.37 (0.49%)
Updated Jul 9, 2024 12:16 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BSX 76.48 +0.37(0.49%)
Will BSX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BSX
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Boston Scientific (BSX) DBS Programming Software Gets CE Mark
Why Boston Scientific (BSX) Dipped More Than Broader Market Today
GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities
Other News for BSX
Buy Rating Justified for Boston Scientific Amidst Positive TCAR Market Adoption and Growth Opportunities
Blackstone’s Voting Power in Corazon Diluted
7 Biotech Stocks to Boost Your Portfolio to Peak Health
3 Record-Breaking Stocks With More Room to Run
RBC Capital Remains a Buy on Boston Scientific (BSX)